Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Strong Buy from Outperform at Raymond James with analyst Matthew McClintock saying he has become more comfortable with the company's risk/return profile, particularly regarding execution risk and valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from In Line at Evercore ISI and to Overweight from Equal Weight at Barclays. 3. Masonite (DOOR) upgraded to Buy from Neutral at Northcoast. 4. BioMarin (BMRN) upgraded to Overweight from Equal Weight at Barclays with analyst Gena Wang saying she sees a favorable risk/reward into the Phase 3 data readout for vosoritide, which she expects will be positive. 5. Envestnet (ENV) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSImpinj (PI) up... To see the rest of the story go to thefly.com. See Story Here

Consensus for FY24 EPS is $1.65. Still sees FY24 revenue $2.7B-$2.8B, consensus $2.77B.

Reports Q1 revenue $649M, consensus $651.79M. "During the quarter, execution across our business led to double digit revenue growth, on a constant currency basis, and an 18% increase in non-GAAP diluted EPS. At the same time, we made rapid progress on advancing our strategic priorities for the year, including accelerating and maximizing the VOXZOGO opportunity, focusing R&D on the most productive assets, and increasing profitability," said CEO Alexander Hardy. "We were pleased with the outcome of our strategic R&D asset review, resulting in the acceleration and prioritization of the most potentially impactful medicines for patients...Quarterly results were driven by strong demand for VOXZOGO, the only approved treatment for children with achondroplasia, and solid contributions from our established enzyme products...Our registration-enabling plans with VOXZOGO in hypochondroplasia, and ongoing discussions with health authorities to align on development plans for idiopathic short stature and pathway conditions are on-track, with all three studies expected to begin enrollment this year."